The aim of the study is to evaluate the effectiveness of different approaches to metaphylaxis of uric acid urolithiasis.
Materials and methods. 46 patients with uric acid urolithiasis were under ambulatory care over the period of 2008-2016: 19 females and 27 males, aged 24 to 66. Recurrent urolithiasis was observed in 42 patients. Kidney stones were found in 32 patients at the beginning of the examination. The patients underwent complex treatment which included records of medical history, general and microbiological examination of urine, biochemical analyses of urine and blood, X-ray and radionuclide methods of diagnosis. Absence of crystalluria and kidney stone formation were regarded as the factors which indicate the success of treatment. Anti-recurrent treatment was prescribed for 32 patients. This included diet therapy which restricted the intake of animal protein, purine bases, animal fats, carbohydrates, potassium and enabled water consumption (more than 2-2.5 liters per day) and the administration of Allopurinol, Blemaren and their combination.
Results. It has been determined that Blemaren and its combined administration with Allopurinol are highly effective for crystalluria prevention. Absence of kidney stones recurrence in patients receiving complex treatment during three years was observed in 93.8% of cases; this parameter was only 30.8% for 13 patients from the control group who underwent only diet therapy which limited the intake of animal protein and purines.
Conclusions. The administration of Blemaren or its combination with Allopurinol is reasonable for the preventive treatment of crystalluria in patients with recurrent uric acid urolithiasis and hyperuricemia and/or hyperuricuria.
Authors declare lack of the possible conflicts of interests.